Advertisement
Advertisement
U.S. markets close in 6 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6100+0.0300 (+1.90%)
As of 09:53AM EDT. Market open.
Advertisement
Sign in to post a message.
  • V
    Vic
    If the case with PSS end, SP-102 approved. Sorrento will be a target to be taken over by big pham. The share price will be more than $50.
  • R
    Rava
    Expert Trader Jeff Bishop Gives Access To His Top Weekly Trading Ideas at No Cost EVERY WEEK! Every Monday at the market open, Jeff will send you his weekly Bullseye Trade. Get immediate access to Jeff Bishop’s best trading ideas and live education each week https://experttrader.tools/WeeklyTradingIdeas
    Get immediate access to Jeff Bishop’s best trading ideas and live education each week.
    Get immediate access to Jeff Bishop’s best trading ideas and live education each week.
    experttrader.tools
  • H
    Hope
    SP 102 FDA fast track December 21...
    Only a matter of time for the rocket to take off. Get on board or get the F outta the way!
    Bullish
  • J
    Joel
    Hey. Would not be surpised if halted today due BO....no moving at all. be well
  • A
    Ariadinvestor
    $AUPH conversation
    To madden frankie C 👌 I swear to God 1) I bought/added MDCO @ 29.195/26.28/20.94; 2) I bought ARIA @ 0.625 on the day when it dropped to 0.50 (all time low) & I sold some around 40 on 3/1/00 when ARIA rose to 48.50 (all time high) & I still held my ARIA shares bought @ 0.80 when Ariad was bought out @ 24 in 2017; 3) I sold some BIIB @ 475 on 3/20/15 when BIIB rose to all time high; 4) I still hold half of my BIDU shares (bought @ 6+) after selling half @ 12+; 5) Before SINA was bought by a private company, I had been holding half of my SINA (bought @ 2+) after selling half @ 22+. cc $srne
    Shares of The Medicines Company were up nearly 23% on Monday after Novartis said Sunday that it had agreed to buy the single-drug, clinical-stage biotech company for $85 per share.
    Shares of The Medicines Company were up nearly 23% on Monday after Novartis said Sunday that it had agreed to buy the single-drug, clinical-stage biotech company for $85 per share.
    www.barrons.com
    Bullish
  • b
    berthabutt365
    Why no insider buying at $1.60? 🤦‍♂️💀
  • A
    Ariadinvestor
    $AUPH conversation
    I don't set stop loss. I don't buy on margin. I don't sell but add more when it pulls back. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. 👌 Please mute me. God bless $SRNE / $AUPH investors. I really mean what I'm saying.
    Bullish
  • P
    Penny
    $10 EASY BY THANKSGIVING ✅
    Bullish
  • A
    Ariadinvestor
    $AUPH conversation
    To madden frankie C 👌 I swear to God that I accepted the $24/share tender offer for my 118,199+ ARIA shares (including what I bought at 0.80 in 2008) in my Fidelity accounts. Let's swear to God that I would burn in hell after dying the most painful death if I were lying here, or you will burn in hell after dying the most painful death. I learned swearing to God on ARIA message board from your husband Yahoo Admin T whose ARIA/AUPH/SRNE position was/is always opposite to mine. T has shorted both $SRNE and $AUPH at bottom prices. Just a matter of time short squeeze is !
    Bullish
  • M
    Mandy
    ji bashed many hard earned investment $$s into the ground by pushing a fake COVID pipeline. I will bash ji until I get even or go broke. ji must not read cdc.gov.
  • V
    Vic
    Looks like today is a good day for SRNE -----up to $2.00
  • J
    Joe
    SRNE share price has advanced in 5 out of the past 6 sessions. Ranging from a low of $1.15 to $1.61 and closing today with a 5-day gain of 25 cents at today's $1.58 close. If the broader market takes a rest tomorrow, we will see a sustained move above $1.60 with a likely test of the $1.75 resistance. It's all uphill from here... with some fits and starts, of course...
    Bullish
  • H
    Hope
    These diamond hands never broke!!
    Bullish
  • M
    Mail
    Shorties disappeared.
    The market is bleeding yet, SRNE is the green giant.
    They brought it down to load up and ride it up... smart money know what to do!
  • A
    Ariadinvestor
    $AUPH conversation
    @Todd/Jim/T ✔"History repeats itself. Both you & I are repeating the Ariad war. I won it as Ariad’s science & pipeline eventually won. I will also win the $AUPH / $SRNE wars as time will let you know it. Will you declare defeating me again by abusing your Yahoo Admin power & deleting my posts/accounts? You’ve left tons of evidences for Verizon to get sued. You don't care about losing your 1st job as a Yahoo Admin because you get paid more from your 2nd job as a paid basher, right? Didn't you say ARIA would drop to $2 & bankrupt right before the $24 buyout?" I've been posting this since 7/5/19.
    Bullish
  • J
    JohnC
    News…. May 17, 2022 - 9:00 am
    • FDA granted IND clearance for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.
    • Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) as well as Bruton's tyrosine kinase (BTK) and has been shown to inhibit extragonadal androgen production in preclinical models due to the interplay between BTK inhibition and 3βHSD.
    • The study will enroll patients with progressive mCRPC harboring the adrenal-permissive HSD3β1(1245C) allele (germline heterozygous or homozygous) and will include two cohorts: abiraterone-naïve and abiraterone-progressing. Presence of the HSD3B1 allele is associated with earlier castration resistance and shorter overall survival.
    • The global market for CRPC for 2021 was $2.7 billion, with the U.S. accounting for 67% ($1.83 billion), and a CAGR of 4.15%, projected to reach $4.56 billion with the U.S. projected to account for 68% ($3.08 billion) by 2031(1).
  • D
    David
    It feels great to see that the professional, highly paid, analysts at Vanguard, State Street, BlackRock, and Fidelity also agree that SRNE is undervalued and a good investment choice at this time. These analysts have access to information that is not available to the average and they are experts in their specific areas. The fact that these analysts are recommending SRNE to their management as a good investment opportunity should make all longs feel much better about their positions.
  • r
    runfast
    ACRX news TODAY, plus CEO news earlier this week, ACRX going to run 200% soon! Dr. Ji, you reading ACRX:
    GOING much HIGHER in the coming weeks, hang on:
    May 19, 2022, ACRX CMO: "We believe that it is this history of stewardship and responsibility, which is included in our latest three-year assessment REMS report as submitted to the FDA"
    May 16, 2022, ACRX CEO: "we're actively discussing strategic relationships with third-parties with a more robust commercial presence that can help maximize distribute value for all stakeholders. Our goal is to enhance the value of DSUVIA with an organization that is better resourced and equipped to carry out the ongoing launch of this very valuable product and even further reduce our cost structure."

    "Now that we have identified where DSUVIA can be successful and increased presence is required in these locations to further grow sales. This is why we're confident that the working with the commercial partner of DSUVIA is a necessary next step. In the meantime, we've restructured our commercial resources to consist of a small virtual sales team focused on procedural suites, which we believe is the most efficient approach."
    Bullish
  • B
    BIG JAKE
    move um on , head um up, Rawhide

    https://www.youtube.com/watch?v=VJeBtHjqJz0
    Rawhide
    www.youtube.com
  • D
    Domingo
    no let's go back to mathematics: a few weeks ago someone was saying that the % held insiders was getting lower becasue they were selling. I corrected him/her by explaining that when the number of standing shares increases the % of your ownership decreases even if you do not sale (#of shares you own/#of total shares)*100. Now the % ownership of the institutions has increased. In this case this absolutely means they are buying more shares because no shares have been retired. So not only the institutions are adding, but as their % ownership is higher even with the dilution we had, they have been BUYING.

    So, little me keep buying what I can
    Bullish
Advertisement
Advertisement